

# Bio-kinetics of single ultrafine particles and agglomerates at the lung barrier

Estelle Durantie, Laura Rodriguez-Lorenzo, Dominic Urban, Alke Fink, Barbara Rothen-Rutishauser

## Motivation

Air pollution is a predominant and recurring concern in our modern society associated to lung and cardiovascular diseases.<sup>1,2</sup> Increased concern has been expressed regarding the adverse health effects elicited by exposure to ultrafine particles (UFP) fraction (<100 nm) of the ambient particulate showing specific toxicological effect.<sup>3,4</sup> In order to better understand the risk associated to UFP inhalation, a clear understanding on their bio-kinetics at the air-blood barrier must be gained. To date, however, the correlation of primary and secondary particle size, i.e. single particles vs. agglomerates, and their cellular uptake and / or translocation across the air-blood tissue barriers are not yet understood.


**GOAL: STUDY BIO-KINETICS OF NANOPARTICLES AT THE HUMAN LUNG TISSUE IN VITRO BARRIER AND COMPARE SINGLE TO AGGLOMERATE PARTICLES**



taken from: <http://www.theguardian.com/uk/2013/jan/27/diesel-engine-fumes-worse-petrol>


## Method

Particles model: Engineered gold nanoparticles<sup>5</sup> (AuNPs)



## In vitro approach to simulate realistic exposure environment


The aim is to analyse the deposition, internalisation and translocation of **nebulized nanoparticles** (single and agglomerates AuNPs) in the human lung by adopting a sophisticated *in vitro* approach that realistically mimics the inhalation of UFP.



## Results

### Deposition


The nebulized particles were homogenously deposited at a dose of 70 and 140 ng/cm<sup>2</sup> as measured by ICP-OES.\*




TEM images of deposited particles after nebulization at a dose of 70 ng/cm<sup>2</sup> of (a) single nanoparticles and (b) agglomerates

### Biological Impact

#### Cell viability





#### Cell morphology



Laser Scanning Microscopy (LSM) of triple cell co-culture 24 h after exposure to (a) NaCl-water solution, (b) single AuNPs, 70 ng/cm<sup>2</sup> and (c) AuNP agglomerates, 70 ng/cm<sup>2</sup>. Immunofluorescence labelling of F-actin (magenta) and nuclei (cyan).

### Bio-distribution

#### Translocation of Au



TEM images of the triple cell co-culture 24 h after exposure to 140 ng/cm<sup>2</sup> of (a) single and (b) agglomerate particles. In (a) and (b) the particles were found in the cytoplasm within a vesicle. In (b), on the bottom left can be seen the PET membrane on which the triple cell co-culture were grown.

\* The dose 140 ng/cm<sup>2</sup> represents the mean of single particles at 130 ng/cm<sup>2</sup> and agglomerates at 150 ng/cm<sup>2</sup>.

## Conclusion


No apparent cytotoxicity, cell layer damage or pro-inflammation was observed after exposure to single nanoparticles or agglomerates at a concentration of 70 and 140 ng/cm<sup>2</sup>. The biological kinetics revealed that the majority of the nanoparticles, singles or agglomerates, were taken up by cells and could be found in macrophages, epithelial and dendritic cells. Only a minor fraction, i.e. less than 3-5 %, was found in the basolateral side for both particles types, which is also corresponding to the translocation rate found *in vivo* for single gold nanoparticles.<sup>8</sup>

A longer exposure time to assess the nanoparticles fate, and exposure to bigger agglomerates should be assessed to see how agglomeration of singles particles can influence the cell up-take and the translocation of nanoparticles across the air-blood tissue barrier. It will broaden our general knowledge on nanoparticle-cell interactions and help to further understand the biological impact of agglomeration of UFPs in comparison to single particles after deposition on the lung cell surface.

### References

- (1) C. A. Pope, D. W. Dockery and J. Schwartz, *Inhal. Toxicol.*, 1995, 7, 1–18.
- (2) K. Donaldson, L. Tran, L. A. Jimenez, R. Duffin, D. E. Newby, N. Mills, W. MacNee and V. Stone, *Part. Fibre Toxicol.*, 2005, 2, 10.
- (3) A. Peters, H. E. Wichmann, T. Tuch, J. Heinrich and J. Heyder, *Am. J. Respir. Crit. Care Med.*, 1997, 155, 1376–1383.
- (4) H. Schulz, V. Harder, A. Ibaldo-Mulli, A. Khandoga, W. Koenig, F. Krombach, R. Radykewicz, A. Stampf, B. Thorand and D. A. Peters, *J. Aerosol Med.*, 2005, 18, 1–22.

- (5) V. Hirsch, C. Kinnear, L. Rodriguez-Lorenzo, C. A. Monnier, B. Rothen-Rutishauser, S. Balog and A. Petri-Fink, *Nanoscale*, 2014, 6, 7325–31.
- (6) A. G. Lenz, E. Karg, B. Lentner, V. Dittich, C. Brandenberger, B. Rothen-Rutishauser, H. Schulz, G. A. Ferron and O. Schmid, *Part. Fibre Toxicol.*, 2009, 6, 32.
- (7) B. M. Rothen-Rutishauser, S. G. Kiama and P. Gehr, *Am. J. Respir. Cell Mol. Biol.*, 2005, 32, 281–289.
- (8) W. G. Kreyling, S. Hirn, W. Möller, C. Schleh, A. Wenk, G. Celik, J. Lipka, M. Schäffler, N. Haberl, B. D. Johnston, R. Sperling, G. Schmid, U. Simon, W. J. Parak and M. Semmler-Behnke, *ACS Nano*, 2014, 8, 222–33.



**Estelle Durantie**  
estelle.durantie@unifr.ch

**Adolphe Merkle Institute**  
Université de Fribourg  
Switzerland